Tonix set for best day in over two months as new fibromyalgia drug hits U.S. market

Tonix Pharmaceuticals Holding

17/11/2025 15:00

Updates

** Shares of drugmaker Tonix Pharmaceuticals TNXP.O rise 7.7% to $17.14 in early trading

** Stock headed for its best day in more than two months, if gains hold

** Co says its new drug Tonmya, the first treatment for fibromyalgia approved in more than 15 years, is now available by prescription at pharmacies across the U.S.

** Fibromyalgia is a chronic disorder causing widespread pain and fatigue

** Co's Tonmya, taken once daily at bedtime, is designed to relieve chronic pain that affects an estimated 10 million Americans, most of whom are women - TNXP

** Approval followed two late-stage trials showing significant pain reduction vs placebo at 14 weeks, co says

** Including session's move, stock down ~49% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))